Axiom Mission 4 will be Peggy Whitson’s second commercial human spaceflight mission with Axiom Space. Photo courtesy of Axiom

NASA veteran Peggy Whitson, a former student and professor at Houston’s Rice University, will command the global crew heading to the International Space Station aboard a private mission directed by Houston-based Axiom Space.

Whitson and her three fellow crew members arrived in Houston on August 6 to train with Axiom Space, NASA, and SpaceX for Axiom Mission 4. The mission is tentatively scheduled for October 2024.

The three astronauts joining Whitson will be:

  • Shubhanshu Shukla, the mission pilot, representing the Indian Space Research Organization
  • Sławosz Uznański, a mission specialist representing the European Space Agency and Poland
  • Tibor Kapu of Hungary, a mission specialist

Axiom Mission 4 will be Whitson’s second commercial human spaceflight mission with Axiom.

“With a culturally diverse crew, we are not only advancing scientific knowledge but also fostering international collaboration. Our previous missions set the stage,” Whitson says in a news release.

Axiom Mission 1 was the first private mission to the space station, Axiom Mission 2 launched the first Saudi woman into space, and

Axiom Mission 3 featured the first Turkish astronaut and first European Space Agency astronaut to fly on a commercial space mission.

With Axiom Mission 4, “we ascend even higher, bringing even more nations to low-Earth orbit and expanding humanity’s reach among the stars,” says Whitton.

From 1981 to 1985, Whitson conducted graduate work in biochemistry at Rice, where she earned a doctoral degree. She was a predoctoral and postdoctoral fellow.

Whitson’s vast experience includes:

  • Adjunct professor in biochemistry and genetics at the University of Texas Medical Branch in Galveston
  • Adjunct assistant professor in biochemistry and genetics at Rice
  • Research biochemist at NASA’s Johnson Space Center
  • Deputy division chief of medical sciences at Johnson Space Center.
  • Chief of station operations at NASA’s Astronaut Office
  • Chief of NASA’s Astronaut Corps
  • Crew member of three NASA space missions

Whitton and the three other astronauts still must gain approval for the Axiom mission from the five organizations that oversee the space station: NASA, the European Space Agency, Roscosmos (the Russian space agency), the Japan Aerospace Exploration Agency, and the Canadian Space Agency.

Axiom 4 “represents Axiom Space’s continued efforts to build opportunity for countries to research, innovate, test, and engage with people around the world while in low-Earth orbit,” says Michael Suffredini, CEO of Axiom Space. “This mission broadens horizons for nations with ambitious goals of advancing scientific, technological, and economic pursuits.”

This mission will emphasize scientific research, tech demonstrations, and space commercialization.

From Florida, the Axiom 4 crew will go to the International Space Station aboard a Falcon 9 rocket and Dragon spacecraft, both made by SpaceX. The crew is expected to spend up to 14 days at the space station.

Axiom Space has announced plans for its third commercial space launch and revealed details of its high-tech spacesuit. Photo courtesy of NASA

Houston space tech company secures third NASA mission, reveals new spacesuits

ready for liftoff

A Houston-based space tech company has revealed details on two of its commercial partnerships with NASA.

NASA and Axiom Space have again signed a mission order for a private astronaut mission to the International Space Station. The mission will commence sometime in November or on and will be from the agency’s NASA’s Kennedy Space Center in Florida. Axiom Mission 3 is the third mission of its kind and, according to a statement from NASA, is expected to be a 14-day trip.

The ISS's Multilateral Crew Operations Panel will approve four proposed crew members and two back up crew submitted by Axiom for the Ax-3 mission. The crew will be expected to train for their flight with NASA, international partners, and SpaceX beginning this spring, according to NASA.

“Axiom Space’s selection to lead the next private astronaut mission to the International Space Station enables us to continue expanding access to nations, academia, commercial entities, and emerging industries to research, test, and demonstrate new technologies in microgravity,” says Michael Suffredini, CEO and president of Axiom Space, in the release. “As NASA’s focus shifts back to the Moon and on to Mars, we are committed to transforming low-Earth orbit into a global space marketplace, where access to space moves beyond the partners of the space station to nations, institutions and individuals with new ideas fueling a thriving human economy beyond Earth.”

Axiom's historic first commercial launch was in spring of 2022, and Ax-2, which will launch the first Saudi astronauts to visit the ISS, is expected to launch this spring. In addition to these two missions, Axiom has been tasked by NASA to develop spacesuits and space station technology.

After several months of working on the suits, Axiom has revealed the details of the technology that will be worn by NASA astronauts returning to the moon on the Artemis III mission that's scheduled to land near the lunar south pole in 2025.

The newly revealed spacesuit will be worn by the first woman and first person of color to visit the moon. Photo courtesy of Axiom Space

“We’re carrying on NASA’s legacy by designing an advanced spacesuit that will allow astronauts to operate safely and effectively on the Moon,” says Suffredini in a statement from the company. “Axiom Space’s Artemis III spacesuit will be ready to meet the complex challenges of the lunar south pole and help grow our understanding of the Moon in order to enable a long-term presence there.”

Called the Axiom Extravehicular Mobility Unit, or AxEMU, the prototype was revealed at Space Center Houston’s Moon 2 Mars Festival today, March 15. According to Axiom, a full fleet of training spacesuits will be delivered to NASA by late this summer.

At the same time as the Ax-3 mission announcement, NASA also announced that it has selected Firefly Aerospace of Cedar Park, Texas, to carry multiple payloads to the far side of the Moon. According to NASA, the commercial lander will deliver two agency payloads, as well as communication and data relay satellite for lunar orbit, which is an European Space Agency collaboration with NASA.

The contract — awarded for around $112 million — is targeted to launch in 2026 through NASA’s Commercial Lunar Payload Services, or CLPS, initiative, and part of the agency’s Artemis program. It's the second award to Firefly under the CLPS initiative.

“The diversity of currently available commercial orbital human spaceflight opportunities is truly astounding. NASA’s commercial crew flights to the space station for our government astronauts paved the way for fully private missions to space like Inspiration4 and Polaris as well as private astronaut missions to the orbiting laboratory like the one we are announcing today,” says Phil McAlister, director of commercial space at NASA Headquarters in Washington, in the release. “We are starting to see the incorporation of space into our economic sphere, and it is going to revolutionize the way people see, use, and experience space.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice research breakthrough paves the way for advanced disease therapies

study up

Bioengineers at Rice University have developed a “new construction kit” for building custom sense-and-respond circuits in human cells, representing a major breakthrough in the field of synthetic biology, which could "revolutionize" autoimmune disease and cancer therapeutics.

In a study published in the journal Science, the team focused on phosphorylation, a cellular process in the body in which a phosphate group is added to a protein, signaling a response. In multicellular organisms, phosphorylation-based signaling can involve a multistage, or a cascading-like effect. Rice’s team set out to show that each cycle in a cascade can be treated as an elementary unit, meaning that they can be reassembled in new configurations to form entirely novel pathways linking cellular inputs and outputs.

Previous research on using phosphorylation-based signaling for therapeutic purposes has focused on re-engineering pathways.

“This opens up the signaling circuit design space dramatically,” Caleb Bashor, assistant professor of bioengineering and biosciences and corresponding author on the study, said in a news release. “It turns out, phosphorylation cycles are not just interconnected but interconnectable … Our design strategy enabled us to engineer synthetic phosphorylation circuits that are not only highly tunable but that can also function in parallel with cells’ own processes without impacting their viability or growth rate.”

Bashor is the deputy director for the Rice Synthetic Biology Institute, which launched last year.

The Rice lab's sense-and-respond cellular circuit design is also innovative because phosphorylation occurs rapidly. Thus, the new circuits could potentially be programmed to respond to physiological events in minutes, compared to other methods, which take hours to activate.

Rice’s team successfully tested the circuits for sensitivity and their ability to respond to external signals, such as inflammatory issues. The researchers then used the framework to engineer a cellular circuit that can detect certain factors, control autoimmune flare-ups and reduce immunotherapy-associated toxicity.

“This work brings us a whole lot closer to being able to build ‘smart cells’ that can detect signs of disease and immediately release customizable treatments in response,” Xiaoyu Yang, a graduate student in the Systems, Synthetic and Physical Biology Ph.D. program at Rice who is the lead author on the study, said in a news release.

Ajo-Franklin, a professor of biosciences, bioengineering, chemical and biomolecular engineering and a Cancer Prevention and Research Institute of Texas Scholar, added “the Bashor lab’s work vaults us forward to a new frontier — controlling mammalian cells’ immediate response to change.”

Greentown Labs names new CEO to lead pioneering climate tech incubator

Transition News

Houston and Boston climate tech incubator Greentown Labs has named Georgina Campbell Flatter as the organization’s incoming CEO.

Flatter will transition to Greentown from her role as co-founder and executive director of TomorrowNow.org, a global nonprofit that studies and connects next-generation weather and climate technologies with communities most affected by climate change.

“We are at a transformational moment in the energy transition, with an unprecedented opportunity to drive solutions in energy production, sustainability, and climate resilience,” Flatter said in a news release. “Greentown Labs is, and has always been, a home for entrepreneurs and a powerhouse of collaboration and innovation.”

Previously, Flatter worked to launch TomorrowNow out of tomorrow.io, a Boston-based AI-powered weather intelligence and satellite technology company. The organization secured millions in climate philanthropy from partners, including the Gates Foundation, which helped deliver cutting-edge climate solutions to millions of African farmers weekly.

Flatter also spent 10 years at the Massachusetts Institute of Technology (MIT), where she was a senior lecturer and led global initiatives at the intersection of technology and social impact. Her research work includes time at Langer Lab and Sun Catalytix, an MIT – ARPA-E-funded spin-out that focused on energy storage solutions inspired by natural photosynthesis. Flatter is also an Acumen Rockefeller Global Food Systems Fellow and was closely involved with Greentown Labs when it was founded in Boston in 2011, according to the release.

“It’s rare to find an individual who has impressive climate and energy expertise along with nonprofit and entrepreneurial leadership—we’re fortunate Georgie brings all of this and more to Greentown Labs,” Bobby Tudor, Greentown Labs Board Chair and Chairman of the Houston Energy Transition Initiative, said in a news release.

Flatter will collaborate with Kevin Dutt, Greentown’s Interim CEO, and also continue to serve on Greentown’s Board of Directors, which was recently announced in December and contributed to a successful $4 million funding round. She’s also slated to speak at CERAWeek next month.

“In this next chapter, I’m excited to build on our entrepreneurial roots and the strength of our ever-growing communities in Boston and Houston,” Flatter added in a news release. “Together, we will unite entrepreneurs, partners, and resources to tackle frontier challenges and scale breakthrough technologies.”

Greentown also named Naheed Malik its new chief financial officer last month. The announcements come after Greentown’s former CEO and president, Kevin Knobloch, announced that he would step down in July 2024 after less than a year in the role.

---

This article originally appeared on our sister site, EnergyCapital.

Houston firm invests $150M in leading 'lab on a chip' medical diagnostics co.

fresh funds

Houston-based health technology investment firm Hamershlag Private Capital Management Limited (HPCM) announced a $150.15 million venture investment in Patho Care LLC.

Patho Care is a “lab on a chip” medical diagnostics company known for its noninvasive point-of-care testing platforms, such as its Raman spectroscopy-based platform.

Its digital point-of-care testing devices are programmable, mobile, and reusable and can detect current or future respiratory bacterial or viral infections. The company says the technology is more cost-effective and provides results faster than traditional diagnostic methods.

“Patho Care LLC is a distinguished leader in healthcare diagnostics through the utilization of a novel approach with spectroscopy and this investment aligns with HPCM’s strategy of partnering with high-potential companies in dynamic industries,” L. Mychal Jefferson, Chairman of Hamershlag, said in a news release.

The transaction was structured as an acquisition and recapitalization using newly issued common stock and cash, which will work through a newly formed entity, PathoCare Holdings Inc. The deal will also facilitate the repayment of Patho Care LLC's existing financial obligations and settle Patho Care’s outstanding notes, helping ensure the company’s financial readiness, according to the release.

The investment will help Patho Care LLC improve operational efficiencies, broaden its service offerings and continue to innovate in the diagnostic testing space. The companies hope the collaboration will help “unlock new growth opportunities while maintaining the company’s legacy of excellence in an emerging technology,” according to a news release.

“Our commitment to delivering transformative value through innovative investments underscores our confidence in Patho Care’s vision and capabilities,” Jefferson added.